The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571
Abstract
Clinical studies have shown that the tyrosine kinase inhibitor STI571 effectively controls BCR-ABL–positive chronic myelogenous leukemia (CML). However, disease progression while on STI571 therapy has been reported, suggesting de novo or intrinsic resistance to BCR-ABL–targeted therapy. To investigate possible mediators of acquired STI571 resistance, K562 cells resistant to 5 μM STI571 (K562-R) were cloned and compared to the parental cell population. K562-R cells had reduced BCR-ABL expression and limited activation of BCR-ABL signaling cascades (Stat 5, CrkL, MAPK). STI571 failed to activate caspase cascades or to suppress expression of survival genes (bcl-xL) in resistant cells. Gene sequencing and tyrosine kinase activity measurements demonstrated that K562-R cells retained wild-type and active BCR-ABL tyrosine kinase that was inhibitable by in vitro incubation with STI571, suggesting that BCR-ABL was not coupled to proliferation or survival of K562-R cells. The src-related kinase LYN was highly overexpressed and activated in K562-R cells, and its inhibition reduced proliferation and survival of K562-R cells while having limited effects of K562 cells. Specimens taken from patients with advanced CML that progressed on STI571 therapy also were analyzed for LYN kinase expression, and they were found to be elevated to a level similar to that of K562-R cells. Comparison of samples from patients taken prior to and following STI571 failure suggested that expression and/or activation of LYN/HCK occurs during disease progression. Together, these results suggest that acquired STI571 resistance may be associated with BCR-ABL independence and mediated in part through overexpression of other tyrosine kinases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Self-citationClinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor
Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer, E. J., Pollok, B. A., & Connelly, P. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.695 · Cited by 1,939
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780
Daley, G. Q., Van Etten, R. A., & Baltimore, D. (1990) · Science · doi:10.1126/science.2406902 · Cited by 1,756
The Biology of Chronic Myeloid Leukemia
Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R., & Kantarjian, H. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907153410306 · Cited by 1,302
Self-citationSawyers, C. L. (2002) · Blood · doi:10.1182/blood.v99.10.3530 · Cited by 1,146
The Molecular Genetics of Philadelphia Chromosome–Positive Leukemias
Epstein, F. H., Kurzrock, R., Gutterman, J. U., & Talpaz, M. (1988) · New England Journal of Medicine · doi:10.1056/nejm198810133191506 · Cited by 837
Self-citationBranford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K., Herrmann, R., Lynch, K. P., & Hughes, T. P. (2002) · Blood · doi:10.1182/blood.v99.9.3472 · Cited by 649
Mahon, F. X., Deininger, M. W. N., Schultheis, B., Chabrol, J., Reiffers, J., Goldman, J. M., & Melo, J. V. (2000) · Blood · doi:10.1182/blood.v96.3.1070 · Cited by 584
le Coutre, P., Tassi, E., Varella-Garcia, M., Barni, R., Mologni, L., Cabrita, G., Marchesi, E., Supino, R., & Gambacorti-Passerini, C. (2000) · Blood · doi:10.1182/blood.v95.5.1758.005a41_1758_1766 · Cited by 484
von Bubnoff, N., Schneller, F., Peschel, C., & Duyster, J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07679-1 · Cited by 464
Weisberg, E., & Griffin, J. D. (2000) · Blood · doi:10.1182/blood.v95.11.3498 · Cited by 401
Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer.
Talamonti, M. S., Roh, M. S., Curley, S. A., & Gallick, G. E. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116200 · Cited by 399
Self-citationHorita, M., Andreu, E. J., Benito, A., Arbona, C., Sanz, C., Benet, I., Prosper, F., & Fernandez-Luna, J. L. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.6.977 · Cited by 366
Gambacorti-Passerini, C. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.20.1641 · Cited by 320
Nieborowska-Skorska, M., Wasik, M. A., Slupianek, A., Salomoni, P., Kitamura, T., Calabretta, B., & Skorski, T. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.8.1229 · Cited by 271
Hofmann, W.-K., Jones, L. C., Lemp, N. A., de Vos, S., Gschaidmeier, H., Hoelzer, D., Ottmann, O. G., & Koeffler, H. P. (2002) · Blood · doi:10.1182/blood.v99.5.1860 · Cited by 239
Hofmann, W.-K., de Vos, S., Elashoff, D., Gschaidmeier, H., Hoelzer, D., Koeffler, H. P., & Ottmann, O. G. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07678-x · Cited by 194
STAT5 Activation by BCR-Abl Contributes to Transformation of K562 Leukemia Cells
de Groot, R. P., Raaijmakers, J. A. M., Lammers, J.-W. J., Jove, R., & Koenderman, L. (1999) · Blood · doi:10.1182/blood.v94.3.1108.415k07_1108_1112 · Cited by 187
Neshat, M. S., Raitano, A. B., Wang, H.-G., Reed, J. C., & Sawyers, C. L. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.4.1179-1186.2000 · Cited by 185
Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.
Danhauser-riedl, S., Warmuth, M., Druker, B. J., Emmerich, B., & Hallek, M. J. (1996) · PubMed · Cited by 182
Missbach, M., Jeschke, M., Feyen, J., Müller, K., Glatt, M., Green, J., & Šuša, M. (1999) · Bone · doi:10.1016/s8756-3282(99)00020-4 · Cited by 168
Dorsey, J. F., Jove, R., Kraker, A. J., & Wu, J. (2000) · PubMed · Cited by 151
Self-citationEra, T., & Witte, O. N. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1737 · Cited by 143
Wang, Y.-Z., Wharton, W., Garcia, R., Kraker, A. J., Jove, R., & Pledger, W. J. (2000) · Oncogene · doi:10.1038/sj.onc.1203548 · Cited by 130
Lionberger, J. M., Wilson, M. B., & Smithgall, T. E. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000126200 · Cited by 115
Sonoyama, J., Matsumura, I., Ezoe, S., Satoh, Y., Zhang, X., Kataoka, Y., Takai, E., Mizuki, M., Machii, T., Wakao, H., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111501200 · Cited by 107
Corey, S. J., Dombrosky-Ferlan, P., Zuo, S., Krohn, E., Donnenberg, A. D., Zorich, P., Romero, G., Takata, M., & Kurosaki, T. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.6.3230 · Cited by 103
Signal transduction by wild-type and leukemogenic Abl proteins
Raitano, A. B., Whang, Y. E., & Sawyers, C. L. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00023-1 · Cited by 102
Bcr-Abl inhibition as a modality of CML therapeutics
Buchdunger, E., Matter, A., & Druker, B. J. (2001) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(01)00022-1 · Cited by 102
Donato, N. J., & Perez, M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.9.5067 · Cited by 98
Self-citationTherapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth
Roginskaya, V. Y., Zuo, S., Caudell, E. G., Nambudiri, G., Kraker, A. J., & Corey, S. (1999) · Leukemia · doi:10.1038/sj.leu.2401429 · Cited by 90
Mechanisms of Transformation by the BCR/ABL Oncogene
Sattler, M., & Griffin, J. D. (2001) · International Journal of Hematology · doi:10.1007/bf02981952 · Cited by 85
Ishikawa, H., Tsuyama, N., Abroun, S., Liu, S., Li, F., Taniguchi, O., & Kawano, M. M. (2002) · Blood · doi:10.1182/blood.v99.6.2172 · Cited by 79
Grishin, A., Azhipa, O., Semenov, I., & Corey, S. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191130798 · Cited by 73
Lyn tyrosine kinase signals cell cycle arrest but not apoptosis in B-lineage lymphoma cells.
Scheuermann, R. H., Racila, E. V., Tucker, T., Yefenof, E., Street, N. E., Vitetta, E. S., Picker, L. J., & Uhr, J. W. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4048 · Cited by 68
Wilson‐Rawls, J., Xie, S., Liu, J., Laneuville, P., & Arlinghaus, R. B. (1996) · PubMed · Cited by 54
Self-citationDonato, N. J., Wu, J. Y., Zhang, L., Kantarjian, H. M., & Talpaz, M. (2001) · Blood · doi:10.1182/blood.v97.9.2846 · Cited by 49
Self-citationChronic myelogenous leukaemia – new therapeutic principles
O'Dwyer, M. E., & Druker, B. J. (2001) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2001.00823.x · Cited by 43
Molecular abnormalities in myeloid leukemias and myelodysplastic syndromes
Sawyers, C. L. (1998) · Leukemia Research · doi:10.1016/s0145-2126(98)00109-x · Cited by 13
Cited by
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Self-citationThe development of imatinib as a therapeutic agent for chronic myeloid leukemia
Deininger, M., Buchdunger, E., & Druker, B. J. (2005) · Blood · doi:10.1182/blood-2004-08-3097 · Cited by 1,253
O'Hare, T., Walters, D. K., Stoffregen, E. P., Jia, T., Manley, P. W., Mestan, J., Cowan-Jacob, S. W., Lee, F. Y., Heinrich, M. C., Deininger, M. W. N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0259 · Cited by 1,036
The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy
Chu, I. M., Hengst, L., & Slingerland, J. M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2347 · Cited by 990
Metadata
- Authors
- Donato, N. J., Wu, J. Y., Stapley, J., Gallick, G., Lin, H., Arlinghaus, R., & Talpaz, M.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2003-01-15
- Volume
- 101
- Issue
- 2
- Pages
- 690-698
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1973720500
- Cited by
- 663
- References
- 41
- FWCI
- 10.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.